Literature DB >> 31281449

Silencing PDK1 limits hypoxia-induced pulmonary arterial hypertension in mice via the Akt/p70S6K signaling pathway.

Ruomin Di1, Zhongzhou Yang2, Peng Xu1, Yingjia Xu1.   

Abstract

The present study aimed to investigate the effect of phosphoinositide-dependent protein kinase-1 (PDK1) on hypoxia-induced pulmonary arterial hypertension (PAH). A mouse model of hypoxia-induced PAH was generated using normal or PDK1-knockout mice. Histological analysis and hemodynamic evaluations were performed to identify the progression of PAH. The expression and phosphorylation of PDK1/protein kinase B (Akt) signaling pathway associated proteins were detected by western blot analysis. Increased lung vessel thickness, right ventricular (RV) systolic pressure (RVSP), RV hypertrophy index (RVHI) values [the RV weight-to-left ventricular (LV) plus septum (S) weight ratio] and PDK1 expression were observed in the hypoxia-induced PAH model compared with the normal control. The phosphorylation of AktT308, proline-rich Akt1 substrate 1 (PRAS40) and S6KT229 was also notably increased in the PAH model compared with the control. The changes of proteins were not observed in the hypoxia treated PDK1flox/+ : Tie2-Cre mice. Similarly, the RVSP and RVHI values, and PDK1 expression were reduced in the hypoxia treated PDK1flox/+: Tie2-Cre mice to a level comparable with those in the control, suggesting that PDK1 partial knockout significantly limited hypoxia-induced PAH. The results of the present study indicate that PDK1 is essential for hypoxia-induced PAH through the PDK1/Akt/S6K signaling cascades.

Entities:  

Keywords:  hypoxia; phosphoinositide-dependent protein kinase-1; protein kinase B; pulmonary arterial hypertension

Year:  2019        PMID: 31281449      PMCID: PMC6591493          DOI: 10.3892/etm.2019.7627

Source DB:  PubMed          Journal:  Exp Ther Med        ISSN: 1792-0981            Impact factor:   2.447


  4 in total

1.  Metabolomics-based mechanism exploration of pulmonary arterial hypertension pathogenesis: novel lessons from explanted human lungs.

Authors:  Jingjing Ding; Chunyan Chu; Zhengsheng Mao; Jiawen Yang; Jie Wang; Li Hu; Peng Chen; Yue Cao; Yan Li; Hua Wan; Dong Wei; Jingyu Chen; Feng Chen; Youjia Yu
Journal:  Hypertens Res       Date:  2022-03-30       Impact factor: 3.872

Review 2.  mTOR Signaling in Pulmonary Vascular Disease: Pathogenic Role and Therapeutic Target.

Authors:  Aleksandra Babicheva; Ayako Makino; Jason X-J Yuan
Journal:  Int J Mol Sci       Date:  2021-02-21       Impact factor: 5.923

3.  Reversal of pulmonary arterial hypertension and neointimal formation by kinin B1 receptor blockade.

Authors:  Dileep Reddy Rampa; Priya Murugesan; Honglu Chao; Huiying Feng; Wenxin Dai; Dongwon Lee; Anton Pekcec; Henri Doods; Dongmei Wu
Journal:  Respir Res       Date:  2021-10-30

4.  Metabolic profile in endothelial cells of chronic thromboembolic pulmonary hypertension and pulmonary arterial hypertension.

Authors:  V F E D Smolders; C Rodríguez; I Blanco; R Szulcek; Wim Timens; L Piccari; Y Roger; X Hu; Constanza Morén; C Bonjoch; L Sebastián; M Castellà; J Osorio; V I Peinado; Harm Jan Bogaard; P H A Quax; M Cascante; J A Barberà; O Tura-Ceide
Journal:  Sci Rep       Date:  2022-02-10       Impact factor: 4.379

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.